{"version":"1.0","type":"link","title":"Neoadjuvant twelve weekly paclitaxel-carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer.","author_name":"Leshem Y 외","author_url":"https://prs-insight.online/author/Leshem%20Y","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/76850","thumbnail_width":1200,"thumbnail_height":630}